A detailed history of Summit Global Investments transactions in Castle Biosciences Inc stock. As of the latest transaction made, Summit Global Investments holds 30,441 shares of CSTL stock, worth $849,303. This represents 0.06% of its overall portfolio holdings.

Number of Shares
30,441
Previous 23,812 27.84%
Holding current value
$849,303
Previous $518,000 67.57%
% of portfolio
0.06%
Previous 0.03%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$17.4 - $31.47 $115,344 - $208,614
6,629 Added 27.84%
30,441 $868,000
Q2 2024

Jul 22, 2024

BUY
$18.84 - $24.94 $448,618 - $593,871
23,812 New
23,812 $518,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $734M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Summit Global Investments Portfolio

Follow Summit Global Investments and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Global Investments, based on Form 13F filings with the SEC.

News

Stay updated on Summit Global Investments with notifications on news.